



US006369116B1

(12) **United States Patent**
Wong et al.

(10) Patent No.: **US 6,369,116 B1**
(45) Date of Patent: **Apr. 9, 2002**

(54) **COMPOSITION AND METHOD FOR TREATING GLAUCOMA**

(75) Inventors: **Vernon Wong, Menlo Park; Lin Peng, San Jose, both of CA (US)**

(73) Assignee: **Oculex Pharmaceuticals, Inc., Sunnyvale, CA (US)**

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 0 days.

(21) Appl. No.: **09/221,002**

(22) Filed: **Dec. 23, 1998**

Related U.S. Application Data

(63) Continuation of application No. 09/160,635, filed on Sep. 24, 1998, which is a continuation of application No. 08/459,134, filed on Jun. 2, 1995, now Pat. No. 5,869,079.

(51) Int. Cl.⁷ **A01N 43/38**

(52) U.S. Cl. **514/913; 424/486; 424/488**

(58) Field of Search **424/484, 486, 424/488; 514/944, 913**

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,478,818 A 10/1984 Shell et al. 424/14
4,863,457 A * 9/1989 Lee
4,865,846 A * 9/1989 Kaufman
4,997,652 A 3/1991 Wong 424/428
5,075,115 A 12/1991 Brine 424/486
5,164,188 A 11/1992 Wong 424/428
5,268,178 A * 12/1993 Calhoun et al.
5,356,629 A 10/1994 Sander et al. 424/422
5,385,887 A 1/1995 Yim et al. 514/12
5,501,856 A 3/1996 Ohtori et al. 424/428
5,656,297 A * 8/1997 Bernstein et al.
5,707,643 A * 1/1998 Ogura

OTHER PUBLICATIONS

R. Baker, "Controlled Release of Biologically Active Agents," *A Wiley-Interscience Publication*, p. 73 (1987).

G. DiColo, "Controlled drug release from implantable matrices based on hydrophobic polymers," *Biomaterials* 1992, vol. 13, No. 12:850-853.

T. Jackanicz et al, "Polylactic Acid As A Biodegradable Carrier For Contraceptive Steroids," *Contraception*, vol. 8, No. 3:227-235.

R. Miller et al, "Degradation Rates of Oral Resorbable Implants (Polylactates and Polyglycolates): Rate Modification with Changes in PLA/PGA Copolymer Ratios," *J. Biomed. Mater. Res.*, vol. 11:711-719 (1977).

J. Heller, "Biodegradable Polymers in Controlled Drug Delivery," *CRC Critical Reviews in Therapeutic Drug Carrier Systems*, vol. 1, Issue 1:39-90.

J. Charles, et al, "Use of Bioerodible Polymers Impregnated with Mitomycin in Glaucoma Filtration Surgery in Rabbits," *Ophthalmology*, Apr. 1991, vol. 98, No. 4: 503-508.

H. Jampel, et al, "Glaucoma Filtration Surgery in Monkeys Using 5-Fluorouridine in Polyanhydride Disks," *Arch Ophthalmol*, Mar. 1990, vol. 108:430-435.

D. Lee, et al, "The Use of Bioerodible Polymers and 5-Fluorouracil in Glaucoma Filtration Surgery," *Investigative Ophthalmology & Visual Science*, Nov. 1988, vol. 29, No. 11:1692-1697.

M. Chang, et al, "Basic Science and Clinical Aspects of Wound Healing in Glaucoma Filtering Surgery," *Journal of Ocular Pharmacology and Therapeutics*, 1998, vol. 14, No. 1:75-95.

D. Lee, et al, "Glaucoma Filtration Surgery in Rabbits Using Bioerodible Polymers and 5-Fluorouracil," *Ophthalmology*, Dec. 1987, vol. 94, No. 12:1523-1530.

T. Smith, et al, "Sustained-release subconjunctival 5-Fluorouracil," *Ophthalmic Surgery Lasers*, Sep. 1996, vol. 27, No. 9:763-767.

* cited by examiner

Primary Examiner—Edward J. Webman

(74) Attorney, Agent, or Firm—David J. Brezner; Todd A. Lorenz; Flehr Hohbach Test Albritton & Herbert LLP

(57) **ABSTRACT**

Implants and methods are provided for modulating wound healing and controlling infection to improve the success of glaucoma filtration surgery. Formulations of one or more therapeutically active agents and a biodegradable polymer provide a substantially constant rate of release for an extended period of time.

19 Claims, 5 Drawing Sheets

